secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001104659-26-021541
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix makes slides with SOL-1 Phase 3 results for AXPAXLI in wet AMD available at Macula Society
--------------------------------------------------------------------------------

- Slides from 49th Macula Society Annual Meeting on Feb 27, 2026 posted on investor website.
- Presentation covers detailed results from SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI).
- AXPAXLI is being developed for treatment of wet age-related macular degeneration (wet AMD).
- Filing does not disclose the actual trial outcomes or numerical results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926021541/0001104659-26-021541-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465926021541/tm267471d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-021541

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer